Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination
Open Access
- 16 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (11), 2000-2008
- https://doi.org/10.1093/cid/ciab555
Abstract
Vaccine-induced neutralizing antibodies are key in combating the COVID-19 pandemic. However, delays of boost immunization due to limited availability of vaccines may leave individuals vulnerable to infection and prolonged or severe disease courses. The emergence of SARS-CoV-2 variants of concern (VOC), B.1.1.7 (United Kingdom), B.1.351 (South Africa), and P.1 (Brazil), may exacerbate this issue, as the latter two are able to evade control by antibodies. We assessed humoral and T cell responses against SARS-CoV-2 WT, VOC and endemic human coronaviruses (hCoV) that were induced after single and double vaccination with BNT162b2. Despite readily detectable IgG against the receptor-binding domain (RBD) of the SARS-CoV-2 S protein at day 14 after a single vaccination, inhibition of SARS-CoV-2 S-driven host cell entry was weak and particularly low for the B.1.351 variant. Frequencies of SARS-CoV-2 WT and VOC specific T cells were low in many vaccinees after application of a single dose and influenced by immunity against endemic hCoV. The second vaccination significantly boosted T cell frequencies reactive for WT, B.1.1.7 and B.1.351 variants. These results call into question whether neutralizing antibodies significantly contribute to protection against COVID-19 upon single vaccination and suggest that cellular immunity is central for the early defenses against COVID-19.Keywords
Funding Information
- Novartis, Gilead, Kinderherz Hannover e.V.
- PARI (14 - 76103-184 CORONA-12/20)
- Federal Ministry of Health (ZMVI1-2520COR804)
- CoCo Study
- State of Lower Saxony
This publication has 32 references indexed in Scilit:
- Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell ResponseClinical Infectious Diseases, 2020
- Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humansScience, 2020
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesNature, 2020
- Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare ProfessionalsInfectious Diseases and Therapy, 2020
- Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19Nature Immunology, 2020
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19Nature, 2020
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controlsNature, 2020
- Pre-existing immunity to SARS-CoV-2: the knowns and unknownsNature Reviews Immunology, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19Nature Medicine, 2020